<?xml version="1.0" encoding="utf-8" standalone="no"?>
<!DOCTYPE file
  SYSTEM 'wikixml.dtd'>
<file type="Talk" date="2024-09-24T08:14:07Z" sourceCorpus="COVID-19" filename="68532309" title="AdCLD-CoV19" url="https://en.wikipedia.org/wiki/AdCLD-CoV19">
	<text>
		<segment id="id68532309">AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co, a company from South Korea.

A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea. In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.
Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022. In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.

 References 














</segment>
	</text>
</file>
